Report cover image

Human Chorionic Gonadotropin Market by Product (Naturally Extracted, Recombinant), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment), End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 197 Pages
SKU # IRE18444601

Description

Human Chorionic Gonadotropin Market by Product (Naturally Extracted, Recombinant), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment), End-User - Global Forecast 2024-2030


The Human Chorionic Gonadotropin Market size was estimated at USD 1.27 billion in 2023 and expected to reach USD 1.37 billion in 2024, at a CAGR 7.53% to reach USD 2.11 billion by 2030.

Global Human Chorionic Gonadotropin Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Human Chorionic Gonadotropin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Chorionic Gonadotropin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Human Chorionic Gonadotropin Market, highlighting leading vendors and their innovative profiles. These include Biocare Medical, LLC, Bristol Myers Squibb Company, Cipla Limited, Ferring B.V., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kamia Biomedical Company, Lee Biosolutions, Inc., Life Medicare & Biotech Private Limited, Livzon Pharmaceutical Group Inc., Lupin Limited, Merck & Co., Inc., Prospec-Tany Technogene Ltd., Qingdao kangyuan Biopharmaceutical Group Co., Ltd., Sanzyme ( P ) Ltd., Scripps Laboratories, Inc., Sun Pharmaceutical Industries Ltd., and Sunrise International Labs Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Chorionic Gonadotropin Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Naturally Extracted

Recombinant

Therapeutic Area
Female Infertility Treatment

Male Hypogonadism

Oligospermia Treatment

End-User
Fertility Clinics

Research Institutions

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Human Chorionic Gonadotropin Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Chorionic Gonadotropin Market?
3. What are the technology trends and regulatory frameworks in the Human Chorionic Gonadotropin Market?
4. What is the market share of the leading vendors in the Human Chorionic Gonadotropin Market?
5. Which modes and strategic moves are suitable for entering the Human Chorionic Gonadotropin Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

197 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Human Chorionic Gonadotropin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidents of infertility among populations
5.1.1.2. Growing investments in the development of fertility clinics
5.1.1.3. Increasing awareness of fertility treatments
5.1.2. Restraints
5.1.2.1. High cost associated with human chorionic gonadotropin therapy
5.1.3. Opportunities
5.1.3.1. Advancements in recombinant technology
5.1.3.2. Emergence of gonadotropin therapy in the healthcare sector
5.1.4. Challenges
5.1.4.1. Possible side effects of human chorionic gonadotropin therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Human Chorionic Gonadotropin Market, by Product
6.1. Introduction
6.2. Naturally Extracted
6.3. Recombinant
7. Human Chorionic Gonadotropin Market, by Therapeutic Area
7.1. Introduction
7.2. Female Infertility Treatment
7.3. Male Hypogonadism
7.4. Oligospermia Treatment
8. Human Chorionic Gonadotropin Market, by End-User
8.1. Introduction
8.2. Fertility Clinics
8.3. Research Institutions
9. Americas Human Chorionic Gonadotropin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Human Chorionic Gonadotropin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.
10. South Korea
10.
11. Taiwan
10.
12. Thailand
10.
13. Vietnam
11. Europe, Middle East & Africa Human Chorionic Gonadotropin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.
10. Nigeria
11.
11. Norway
11.
12. Poland
11.
13. Qatar
11.
14. Russia
11.
15. Saudi Arabia
11.
16. South Africa
11.
17. Spain
11.
18. Sweden
11.
19. Switzerland
11.
20. Turkey
11.
21. United Arab Emirates
11.
22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Biocare Medical, LLC
13.1.2. Bristol Myers Squibb Company
13.1.3. Cipla Limited
13.1.4. Ferring B.V.
13.1.5. Fresenius Kabi AG
13.1.6. Intas Pharmaceuticals Ltd.
13.1.7. Kamia Biomedical Company
13.1.8. Lee Biosolutions, Inc.
13.1.9. Life Medicare & Biotech Private Limited
13.1.
10. Livzon Pharmaceutical Group Inc.
13.1.
11. Lupin Limited
13.1.
12. Merck & Co., Inc.
13.1.
13. Prospec-Tany Technogene Ltd.
13.1.
14. Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
13.1.
15. Sanzyme ( P ) Ltd.
13.1.
16. Scripps Laboratories, Inc.
13.1.
17. Sun Pharmaceutical Industries Ltd.
13.1.
18. Sunrise International Labs Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2023 VS 2030
FIGURE 3. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HUMAN CHORIONIC GONADOTROPIN MARKET DYNAMICS
FIGURE 7. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 10. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us